Physician profile
Gary Bruce Pinta
NPI 1023008752
$14,096.04
in general payments reported to CMS, 2019-2025
53 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $1,066 · 2021: $2,135 · 2022: $2,515 · 2023: $2,416 · 2024: $2,321 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,737.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,196.32 | 2020-2025 | |
| Novo Nordisk INC | $1,624.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,246.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,198.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $802.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $742.07 | 2020-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $738.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $598.80 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $521.69 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $513.86 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.35 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.68 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $261.08 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $244.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $227.55 | 2021-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Pinta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.